Dimensionality reduction enables MRD visualization in single-sample flow cytometric analysis in acute leukemia.

FlowLOT: Linearized Optimal Transport for Flow Cytometry Analysis.

FlowLOT is introduced, an optimal-transport-based framework that models the single-cell measurement data of a pa- tient sample as an empirical cellular distribution and maps it directly into a fixed-length feature vector and unifies high-dimensional classification, interpretable visualization, and continuous quantitati...

Old data, new tricks: Comprehensive computational analysis of 10 years of multi-center EuroFlow acute myeloid leukemia diagnostic immunophenotypic data.

Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight ce...

High-Content Imaging Workflow for Single-Cell Drug Response Profiling of Acute Myeloid Leukemia Subtypes.

A high-content fluorescence imaging workflow for quantitative drug response profiling (DRP) in AML at single-cell resolution and establishes a scalable functional phenomics platform for high-resolution drug profiling and phenotypic stratification in AML.

Morphological Analysis for Acute Lymphocytic Leukemia Identification in Peripheral Blood Microscope Images Using ImageJ

Acute Lymphocytic Leukemia (ALL) is a hematologic malignancy characterized by abnormal proliferation of immature lymphocytes in bone marrow and peripheral blood. Timely identification of blast-cell morphology in peripheral smear images can support early screening and reduce manual review burden. This paper presents an...

Measurable Residual Disease.

Single-Cell proteomics discerns patient-specific subpopulations in pediatric B-cell acute lymphoblastic leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, representing ∼30% of pediatric cancers and ∼80-85% of pediatric ALL cases. Despite high remission rates, relapse remains a major challenge, often driven by therapy-resistant subpopulations, which are masked in bulk analysis, thus limiting...